Current Approach to Diagnosis and Management of Chronic Lymphocytic Leukemia

Mayo Clinic Proceedings

Volumn 79, Issue 3, 2004, Pages 388-398

  Shanafelt, Tait D ^a   Call, Timothy G ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISONE; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; VINCRISTINE SULFATE;

AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LYMPHOMA; BLOOD SMEAR; BONE MARROW SUPPRESSION; CANCER STAGING; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CONSULTATION; EARLY DIAGNOSIS; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HERPES; HIGH RISK POPULATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; INFECTION; LYMPHOCYTOPENIA; NEUTROPENIA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SECOND CANCER; STEM CELL TRANSPLANTATION; VACCINATION;

EID: 1442306830     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.3.388     Document Type: Review

References (79)

1. Call TG, Phyliky RL, Noël P, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc. 1994;69:323-328.
2. Rozman C, Bosch F, Montserrat E. Chronic lymphocytic leukemia: a changing natural history? Leukemia. 1997;11:775-778.
3. Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia? Haematologica. 2001;86:8-12.
4. Knauf WU, Langenmayer I, Ehlers B, et al. Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 1997;27:523-532.
5. Catovsky D, Fooks J, Richards S, MRC Working Party on Leukaemia in Adults. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival: a report from the MRC CLL 1 trial. Br J Haematol. 1989;72:141-149.
6. Zent CS, Kyasa MJ, Evans R, Schichman SA. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer. 2001;92:1325-1330.
7. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
8. Rawstron AC, de Tute R, O'Connor SJ, Richards SJ, Jack AS, Hillmen P. The natural history of "early CLL" [abstract]. Blood. 2003;102(11, pt 1): 188a. Abstract 656.
9. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
10. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.
11. Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, eds. Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. New York, NY: Alan R Liss; 1987:253-264.
12. Mandelli F, De Rossi G, Mancini P, et al. Prognosis in chronic lymphocytic leukemia: a retrospective multicentric study from the GIMEMA group. J Clin Oncol. 1987;5:398-406.
13. Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer. 1977;40:855-864.
14. Jaksic B, Vitale B, Hauptmann E, Planinc-Peraica A, Ostojic S, Kusec R. The roles of age and sex in the prognosis of chronic leukaemias: a study of 373 cases. Br J Cancer. 1991;64:345-348.
15. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986;62:567-575.
16. Vinolas N, Reverter JC, Urbano-Ispizua A, Montserrat E, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukemia: an update of its prognostic significance. Blood Cells. 1987;12:457-470.
17. Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer. 1987;60:2712-2716.
18. Keating MJ, Lerner S, Kantarjian H, Freireich EJ, O'Brien S. The serum β2-microglobulin (β2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL) [abstract]. Blood. 1995;86(suppl 1):606a. Abstract 2412.
19. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
20. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324:1385-1393.
21. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990;323:720-724.
22. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
23. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515-1525.
24. Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today. 1994;15:288-294.
25. Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood. 1997;89:4153-4160.
26. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
27. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
28. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004;103:1202-1210.
29. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416.
30. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023-1029.
31. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood. 2001;98:2633-2639.
32. Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol. 2002;116:142-150.
33. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98:181-186.
34. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639-1647.
35. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med. 2001;194:1625-1638.
36. Jelinek DF, Tschumper RC, Stolovitzky GA, et al. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res. 2003;1:346-361.
37. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951.
38. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
39. Rassenti LZ, Huynh L, Toy TL, et al. Zap-70 is a more reliable marker of disease progression risk than immunoglobulin mutation status in chronic lymphocytic leukemia [abstract]. Blood. 2003;102(11, pt 1):34a. Abstract 106.
40. Durig J, Nuckel H, Cremer M, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia. 2003;17:2426-2434.
41. H mutation status? [abstract]. Blood. 2003;102(11, pt 1): 34a. Abstract 108.
42. Grever MR, Dewald GW, Lucas DM, et al. ZAP-79 protein expression varies by interphase cytogenetic group and may predict disease progression to requirement of treatment among select genetic groups in patients with chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2003;102(11, pt 1):73a. Abstract 244.
43. Kallander CF, Simonsson B, Hagberg H, Gronowitz JS. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer. 1984;54:2450-2455.
44. Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 1996;22:439-447.
45. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood. 1999;93:1732-1737.
46. Di Raimondo F, Giustolisi R, Lerner S, et al. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001;12:621-625.
47. Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97:256-263.
48. Giles FJ, Bekele BN, O'Brien S, et al. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol. 2003;121:578-585.
49. Molica S, Levato D, Cascavilla N, Levato L, Musto P. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol. 1999;62:117-122.
50. Molica S, Levato D, Dell'Olio M, et al. Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia: implications for prognosis. Haematologica. 1996;81:428-433.
51. Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood. 1996;88:4259-4264.
52. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia. 2000;14:1414-1418.
53. Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;107:605-610.
54. Shustik C, Mick R, Silver R, Sawitsky A, Rai K, Shapiro L. Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol. 1988;6:7-12.
55. Dighiero G, Maloum K, Desablens B, et al, French Cooperative Group on Chronic Lymphocytic Leukemia. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med. 1998;338:1506-1514.
56. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
57. Schulz H, Klein SK, Rehwald U, et al, German CLL Study Group. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002;100:3115-3120.
58. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14.
59. Keating MJ, Manshouri T, O'Brien O, et al. A high proportion of true complete remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukemia. Program Proc Am Soc Clin Oncol. 2003;22:569. Abstract 2289.
60. Keating MJ, Flinn I, Jain V, Binet JL, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554-3561.
61. Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol. 2003;21:1874-1881.
62. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003;101:3413-3415.
63. Montserrat E, Esteve J, Schmitz N, et al, International Project for CLL/Transplants. Autologous stem-cell tranplantation (ASCT) for chronic lymphocytic leukemia (CLL): results in 107 patients [abstract]. Blood. 1999;94(suppl 1):397a. Abstract 1758.
64. Esteve J, Montserrat E, Dreger P, et al, International Project on CLL/Transplant. Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): outcome and prognostic factors after autologous and allogeneic transplants [abstract]. Blood. 2001;98(11, pt 1):482a. Abstract 2013.
65. Dreger P, van Biezen A, Brand R, et al, Chronic Leukemia Working Party, European Blood and Marrow Transplant Group (EBMT). Prognostic factors for survival after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): the EBMT experience [abstract]. Blood. 2000;96(11, pt 1):482a. Abstract 2071.
66. Dreger P, von Neuhoff N, Sonnen R, et al. Efficacy and prognostic implications of early autologous stem cell transplantation for poor-risk chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2000;96(11, pt 1):483a. Abstract 2076.
67. Gribben JG, Neuberg D, Soiffer RJ, et al. Autologous versus allogeneic bone marrow transplantation for patients with poor prognosis CLL [abstract]. Blood. 1998;92(suppl 1):322a. Abstract 1320.
68. Pavletic S, Khouri I, King R, et al. HLA-matched unrelated donor (mud) bone marrow transplantation for B-cell chronic lymphocytic leukemia (results from the CLL Working Group, National Marrow Donor Program) [abstract]. Program Proc Am Soc Clin Oncol. 2000;19:4a. Abstract 8.
69. Pavletic ZS, Arrowsmith ER, Bierman PJ, et al. Outcome of allogeneic stem cell tranplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000;25:717-722.
70. Esteve J, Villamor N, Colomer D, et al. Different significance of minimal residual disease (MRD) after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia (CLL): prognostic and therapeutic implications [abstract]. Blood. 2001;98(11, pt 1):763a. Abstract 3179.
71. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.
72. Dreger P, van Biezen A, Brand R, et al. Allogeneic stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL) using intensity-reduced conditioning: a survey of the European Blood and Marrow Transplant Group (EBMT) [abstract]. Blood. 2001;98(11, pt 1):743a. Abstract 3095.
73. Schetelig J, Held TK, Bornhäuser M, et al. Nonmyeloablative allogeneic stem cell transplants in chronic lymphocytic leukemia from related and unrelated donors [abstract]. Blood. 2000;96(11, pt 1):200a. Abstract 857.
74. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004;32:28-35.
75. Dreger P, Stilgenbauer S, Benner A, et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood. December 11, 2003 [Epub ahead of print].
76. Kyasa MJ, Parrish RS, Schichman SA, Zent CS. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2003;74:1-8.
77. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol. 1998;25:80-97.
78. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000;95:2786-2792.
79. Kyasa MJ, Hazlett L, Parrish RS, Schichman SA, Zent CS. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma. 2004;45:507-513.